Which has preferable valuation & earnings, TARA or CADL?

Candel Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.35 N/A Candel Therapeutics N/A N/A -$38.18M -$1.41 N/A

Is TARA or CADL more profitable?

Protara Therapeutics' return on equity of -41.72% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -41.72% -38.78% Candel Therapeutics N/A -76.98% -48.50%

Which has better valuation & earnings, CLYM or TARA?

Climb Bio is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Climb Bio N/A N/A -$59.85M -$0.83 N/A Protara Therapeutics N/A N/A -$57.44M -$1.35 N/A

Is CLYM or TARA more profitable?

Climb Bio's return on equity of -31.79% beat Protara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.79% -30.79% Protara Therapeutics N/A -41.72% -38.78%

Which has higher valuation & earnings, ANNX or TARA?

Annexon is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.16 N/A Protara Therapeutics N/A N/A -$57.44M -$1.35 N/A

Is ANNX or TARA more profitable?

Protara Therapeutics' return on equity of -41.72% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Protara Therapeutics N/A -41.72% -38.78%

Protara Therapeutics (TARA) Competitors

$2.70 -0.06 (-2.17%)

Closing price 04:00 PM Eastern

Extended Trading

$2.78 +0.08 (+2.93%)

As of 04:35 PM Eastern

Compare

TARA vs. GERN, CADL, CLYM, ANNX, and DBVT

Should you buy Protara Therapeutics stock or one of its competitors? Protara Therapeutics's main competitors and comparable companies include Geron (GERN), Candel Therapeutics (CADL), Climb Bio (CLYM), Annexon (ANNX), and DBV Technologies (DBVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Protara Therapeutics compare to Geron?

Geron (NASDAQ:GERN) and Protara Therapeutics (NASDAQ:TARA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Geron currently has a consensus target price of $4.00, suggesting a potential upside of 229.22%. Protara Therapeutics has a consensus target price of $26.25, suggesting a potential upside of 888.70%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protara Therapeutics is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Geron had 3 more articles in the media than Protara Therapeutics. MarketBeat recorded 3 mentions for Geron and 0 mentions for Protara Therapeutics. Geron's average media sentiment score of 0.51 beat Protara Therapeutics' score of 0.00 indicating that Geron is being referred to more favorably in the media.

Company	Overall Sentiment
Geron	Positive
Protara Therapeutics	Neutral

Protara Therapeutics has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.25	-$83.50M	-$0.11	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A

Protara Therapeutics has a net margin of 0.00% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Protara Therapeutics	N/A	-41.72%	-38.78%

73.7% of Geron shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 1.7% of Geron shares are held by company insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Geron has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

Summary

Protara Therapeutics beats Geron on 8 of the 15 factors compared between the two stocks.

How does Protara Therapeutics compare to Candel Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and Candel Therapeutics (NASDAQ:CADL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

In the previous week, Candel Therapeutics had 13 more articles in the media than Protara Therapeutics. MarketBeat recorded 13 mentions for Candel Therapeutics and 0 mentions for Protara Therapeutics. Candel Therapeutics' average media sentiment score of 0.49 beat Protara Therapeutics' score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Protara Therapeutics	Neutral
Candel Therapeutics	Neutral

Protara Therapeutics' return on equity of -41.72% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-41.72%	-38.78%
Candel Therapeutics	N/A	-76.98%	-48.50%

38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 7.6% of Protara Therapeutics shares are held by insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Candel Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A

Protara Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.32, indicating that its share price is 132% less volatile than the broader market.

Protara Therapeutics currently has a consensus price target of $26.25, suggesting a potential upside of 888.70%. Candel Therapeutics has a consensus price target of $20.14, suggesting a potential upside of 97.40%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Protara Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Candel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Protara Therapeutics beats Candel Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Protara Therapeutics compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Protara Therapeutics (NASDAQ:TARA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Climb Bio's return on equity of -31.79% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.79%	-30.79%
Protara Therapeutics	N/A	-41.72%	-38.78%

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by insiders. Comparatively, 7.6% of Protara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Climb Bio is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A

Climb Bio has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

Climb Bio presently has a consensus price target of $26.92, indicating a potential upside of 149.29%. Protara Therapeutics has a consensus price target of $26.25, indicating a potential upside of 888.70%. Given Protara Therapeutics' higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Climb Bio had 2 more articles in the media than Protara Therapeutics. MarketBeat recorded 2 mentions for Climb Bio and 0 mentions for Protara Therapeutics. Climb Bio's average media sentiment score of 0.00 equaled Protara Therapeutics'average media sentiment score.

Company	Overall Sentiment
Climb Bio	Neutral
Protara Therapeutics	Neutral

Summary

Climb Bio beats Protara Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Protara Therapeutics compare to Annexon?

Annexon (NASDAQ:ANNX) and Protara Therapeutics (NASDAQ:TARA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Protara Therapeutics' return on equity of -41.72% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Protara Therapeutics	N/A	-41.72%	-38.78%

Annexon is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A

Annexon has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market.

In the previous week, Annexon had 11 more articles in the media than Protara Therapeutics. MarketBeat recorded 11 mentions for Annexon and 0 mentions for Protara Therapeutics. Annexon's average media sentiment score of 1.04 beat Protara Therapeutics' score of 0.00 indicating that Annexon is being referred to more favorably in the media.

Company	Overall Sentiment
Annexon	Positive
Protara Therapeutics	Neutral

38.1% of Protara Therapeutics shares are owned by institutional investors. 10.3% of Annexon shares are owned by company insiders. Comparatively, 7.6% of Protara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Annexon presently has a consensus price target of $15.29, indicating a potential upside of 264.38%. Protara Therapeutics has a consensus price target of $26.25, indicating a potential upside of 888.70%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Protara Therapeutics beats Annexon on 9 of the 13 factors compared between the two stocks.

How does Protara Therapeutics compare to DBV Technologies?

Protara Therapeutics (NASDAQ:TARA) and DBV Technologies (NASDAQ:DBVT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Protara Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Protara Therapeutics' return on equity of -41.72% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-41.72%	-38.78%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

Protara Therapeutics has higher earnings, but lower revenue than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A
DBV Technologies	$5.64M	120.63	-$146.95M	-$3.51	N/A

Protara Therapeutics has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -1.04, indicating that its stock price is 204% less volatile than the broader market.

Protara Therapeutics presently has a consensus price target of $26.25, suggesting a potential upside of 888.70%. DBV Technologies has a consensus price target of $48.50, suggesting a potential upside of 348.24%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Protara Therapeutics is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
DBV Technologies	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 1.1% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, DBV Technologies had 12 more articles in the media than Protara Therapeutics. MarketBeat recorded 12 mentions for DBV Technologies and 0 mentions for Protara Therapeutics. DBV Technologies' average media sentiment score of 0.24 beat Protara Therapeutics' score of 0.00 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Protara Therapeutics	Neutral
DBV Technologies	Neutral

Summary

Protara Therapeutics beats DBV Technologies on 11 of the 15 factors compared between the two stocks.

Get Protara Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TARA vs. The Competition

Export

Metric	Protara Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$159.57M	$3.84B	$7.10B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-2.00	12.99	274.33	26.05
Price / Sales	N/A	1,288.68	601.06	89.40
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	0.71	16.63	10.92	6.31
Net Income	-$57.44M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-17.68%	-3.05%	-2.11%	-1.67%
1 Month Performance	-31.47%	-10.75%	-6.34%	-3.94%
1 Year Performance	-36.02%	21.11%	8.81%	2.77%

Protara Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TARA Protara Therapeutics	1.4983 of 5 stars	$2.70 -2.2%	$26.25 +872.2%	-37.4%	$159.57M	N/A	N/A	51	High Trading Volume
GERN Geron	1.8788 of 5 stars	$1.30 flat	$4.00 +207.7%	-14.2%	$835.22M	$204.56M	N/A	258
CADL Candel Therapeutics	2.9509 of 5 stars	$11.21 +3.3%	$20.14 +79.7%	+83.4%	$830.23M	N/A	N/A	55	News Coverage Analyst Forecast Gap Up
CLYM Climb Bio	2.1848 of 5 stars	$13.64 -2.9%	$26.92 +97.4%	+461.9%	$806.98M	N/A	N/A	29
ANNX Annexon	3.6333 of 5 stars	$4.22 -0.2%	$15.14 +258.8%	+36.0%	$801.92M	N/A	N/A	92	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TARA) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protara Therapeutics (TARA) Competitors

TARA vs. GERN, CADL, CLYM, ANNX, and DBVT

How does Protara Therapeutics compare to Geron?

Summary

How does Protara Therapeutics compare to Candel Therapeutics?

Summary

How does Protara Therapeutics compare to Climb Bio?

Summary

How does Protara Therapeutics compare to Annexon?

Summary

How does Protara Therapeutics compare to DBV Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA vs. The Competition

Protara Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protara Therapeutics (TARA) Competitors

TARA vs. GERN, CADL, CLYM, ANNX, and DBVT

How does Protara Therapeutics compare to Geron?

Do analysts prefer GERN or TARA?

Does the media prefer GERN or TARA?

Which has preferable earnings and valuation, GERN or TARA?

Is GERN or TARA more profitable?

Do insiders and institutionals hold more shares of GERN or TARA?

Which has more volatility and risk, GERN or TARA?

Summary

How does Protara Therapeutics compare to Candel Therapeutics?

Does the media refer more to TARA or CADL?

Is TARA or CADL more profitable?

Do insiders & institutionals have more ownership in TARA or CADL?

Which has preferable valuation & earnings, TARA or CADL?

Which has more risk and volatility, TARA or CADL?

Do analysts recommend TARA or CADL?

Summary

How does Protara Therapeutics compare to Climb Bio?

Is CLYM or TARA more profitable?

Do insiders and institutionals believe in CLYM or TARA?

Which has better valuation & earnings, CLYM or TARA?

Which has more volatility & risk, CLYM or TARA?

Do analysts recommend CLYM or TARA?

Does the media prefer CLYM or TARA?

Summary

How does Protara Therapeutics compare to Annexon?

Is ANNX or TARA more profitable?

Which has higher valuation & earnings, ANNX or TARA?

Which has more risk and volatility, ANNX or TARA?

Does the media favor ANNX or TARA?

Do insiders & institutionals believe in ANNX or TARA?

Do analysts recommend ANNX or TARA?

Summary

How does Protara Therapeutics compare to DBV Technologies?

Is TARA or DBVT more profitable?

Which has stronger earnings & valuation, TARA or DBVT?

Which has more risk and volatility, TARA or DBVT?

Do analysts rate TARA or DBVT?

Do institutionals & insiders hold more shares of TARA or DBVT?

Does the media refer more to TARA or DBVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA vs. The Competition

Protara Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools